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Abstract: Facioscapulohumeral muscular dystrophy (FSHD) is characterized by incomplete
penetrance and intra-familial clinical variability. The disease has been associated with the genetic
and epigenetic features of the D4Z4 repetitive elements at 4q35. Recently, D4Z4 hypomethylation
has been proposed as a reliable marker in the FSHD diagnosis. We exploited the Italian Registry for
FSHD, in which FSHD families are classified using the Clinical Comprehensive Evaluation Form
(CCEF). A total of 122 index cases showing a classical FSHD phenotype (CCEF, category A) and
110 relatives were selected to test with the receiver operating characteristic (ROC) curve, the diagnostic
and predictive value of D4Z4 methylation. Moreover, we performed DNA methylation analysis
in selected large families with reduced penetrance characterized by the co-presence of subjects
carriers of one D4Z4 reduced allele with no signs of disease or presenting the classic FSHD clinical
phenotype. We observed a wide variability in the D4Z4 methylation levels among index cases
revealing no association with clinical manifestation or disease severity. By extending the analysis to
family members, we revealed the low predictive value of D4Z4 methylation in detecting the affected
condition. In view of the variability in D4Z4 methylation profiles observed in our large cohort,
we conclude that D4Z4 methylation does not mirror the clinical expression of FSHD. We recommend
that measurement of this epigenetic mark must be interpreted with caution in clinical practice.
Keywords: FSHD; D4Z4 reduced allele; DNA methylation; genotype–phenotype correlation;
molecular diagnosis
1. Introduction
Facioscapulohumeral muscular dystrophy (FSHD) (OMIM#158900) is characterized by insidious
onset and progressive wasting of a highly selective set of muscle groups [1]. FSHD is the third most
common hereditary myopathy with a prevalence of 1 in 20,000 [2]. It has been historically classified as
a fully penetrant autosomal dominant disease [1], even though recent genotype–phenotype studies
revealed reduced penetrance of disease, which can vary substantially among different families [3–5].
FSHD has been genetically linked to the reduction of an integral number of tandem 3.3-kilobase
D4Z4 repeat units (RU) located on chromosome 4q35 [6,7]. Although nearly identical D4Z4 sequences
reside on chromosome 10q26 [8], only subjects with a D4Z4 reduced array (DRA) on chromosome 4,
but not on chromosome 10, develop FSHD [9]. The size of the D4Z4 arrays on chromosomes 4 and
10 is assessed by digestion with EcoRI, which cuts outside the repeat array, followed by pulse-field
gel electrophoresis (PFGE) and Southern blotting [10]. Based on these results, EcoRI alleles larger
than 50 kb (≥11 D4Z4 RU) originating from chromosome 4q have been considered normal, whereas
alleles of 35 kb or shorter (≤8 D4Z4 RU) have been considered diagnostic for FSHD and considered
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highly sensitive and specific [11,12]. Through the years the threshold size of D4Z4 alleles has been
increased from the original 28 kb (6 RU) [6] to 35 kb (8 RU) [7], with FSHD cases carrying D4Z4 alleles of
38-41 kb (9–11 RU) considered borderline alleles [13]. To complicate FSHD molecular diagnosis, several
genotype–phenotype studies have shown that D4Z4 alleles with 4-8 RU are also present in 3% of the
general population [4,10,14]. Moreover, 5–10% of FSHD patients carry D4Z4 arrays of size within the
range of the general healthy population (11 RU or more) on both 4q chromosomes [14,15]. Molecularly,
these subjects represent a second form of the disease, FSHD2. Therefore, the number of D4Z4 RU at
4q35 does not per se characterize the disease. As a matter of fact, genotype–phenotype studies have
shown a large spectrum of clinical phenotypes in myopathic subjects carrying a D4Z4 reduced allele
as well as reduced penetrance among relatives carrying the same D4Z4 reduced allele [5,13,16–19].
This great heterogeneity has generated the need for additional markers to support FSHD diagnosis,
genetic counseling, and patients’ stratification for clinical trials.
From this perspective, it has been shown that reduction of DNA methylation of the 4q35 D4Z4
array characterizes both FSHD1 and FSHD2 [20,21]. Furthermore, roughly 85% of FSHD2 patients
carry heterozygous dominant mutations in the SMCHD1 (structural maintenance of chromosomes flexible
hinge domain containing-1) gene [22], which encodes an epigenetic regulator of specific loci including
D4Z4 arrays. It has been thus proposed that repeat contraction (FSHD1) or SMCHD1 mutation (FSHD2)
is involved in chromatin changes resulting in reduced D4Z4 DNA methylation, which characterizes
disease. It has thus been suggested that molecular diagnosis of FSHD can be based on genetic (presence
or absence of DRA) and epigenetic (D4Z4 hypomethylation and/or SMCHD1 variant) characteristics.
The methylation status of the D4Z4 arrays can be measured by using methylation-sensitive
restriction enzyme (MSRE) analysis, which measures the methylation status of a single CpG dinucleotide
in the proximal-most D4Z4 RU of the 4q and 10q arrays [22–24], or using sodium bisulfite sequencing
(BSS), which measures the percentage of methylated CpG dinucleotides across a region either within
each D4Z4 RU [25–27] or specifically in the distal-most 4q35 D4Z4 RU [27].
Here, we present the results of a large consecutive study of D4Z4 methylation on index cases
presenting classical features of FSHD and their relatives to test the association of genetic, epigenetic,
and clinical features. All subjects were clinically examined by applying the Comprehensive Clinical
Evaluation Form (CCEF), which assesses the degree of motor impairment, describes the observed
phenotypic features, and captures the wide clinical spectrum of FSHD families [19]. D4Z4 Methylation
status has been measured using MSRE analysis in all subjects and BSS of the distal-most 4q35 RU in
selected families.
2. Results
2.1. A Highly Variable Range of D4Z4 Methylation Level in FSHD ndex Cases
We investigated D4Z4 methylation status at 4q35 and 10q26 through MSRE1 in 122 FSHD1 index
cases with FSHD clinical score ≥1 at the time of evaluation (age at examination ≥10 years). As shown in
Figure 1A and Table Sa, we observed a highly variable distribution of D4Z4 methylation level ranging
from 3% to 74%. Remarkably, through MRSE2 assay, Figure 1B, we found that 87 out of 122 FSHD
index cases (71%) displayed a level of methylation higher than 25% on chromosome 4q35. Statistical
analysis showed no significant association between the MSRE1 level of D4Z4 methylation and the
FSHD score (b = −0.035, p = 0.140; R2 = 0.033).
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Figure 1. Assessment of DNA methylation level in facioscapulohumeral muscular dystrophy (FSHD) 
index cases using MRSE1 (A) and MRSE2 (B) approaches: (A) The crude relationship between the two 
parameters is not significant (b = −0.028, p = 0.236; R2 = 0.012). The strength of the relationship does 
not improve when adjusting for the age of patient, as we find no significant association between level 
of D4Z4 methylation and FSHD score (b = −0.035, p = 0.140; R2 = 0.033). (B) The crude relationship is 
very weak but statistically significant (b = −0.047, p = 0.048; R2 = 0.036). The strength of the relationship 
improves adjusting for the age of patient (b=−0.050, p = 0.036, R2 = 0.057). 
2.2. Analysis of D4Z4 Methylation in FSHD1 and FSHD2 
It has been reported that D4Z4 methylation level is lower in FSHD2 than in FSHD1 because all 
four D4Z4 arrays (2 at 4q35 and 2 at 10q26) are epigenetically dysregulated [20,21]. Originally, the 
threshold of 25% of total D4Z4 DNA methylation was used as a cutoff to identify FSHD2 affected 
subjects [22]. In a later work, the threshold was subsequently moved up to 30% [28]. In our cohort, 
we found that out of 34 index cases with classical FSHD phenotype carrying normal-sized D4Z4 
Figure 1. A se sment of DNA methylation level in facioscapulohumeral muscular dystrophy (FSHD)
index cases using MRSE1 (A) and MRSE2 (B) approaches: (A) The crude relationship betw en the two
parameters is not si ifica t ( 0.028, p = 0.236; R2 = 0.012). The strength of the relationship does
not improve when adjusting for the age of patient, as we find no significant a sociation betw en level
of D4Z4 ethylation a 0.035, p 0.140; R2 = 0.0 3). (B) The crude relationship is
very eak but statisti ll fi 0.047, p = 0.048; R2 = .036). The strength of the relationship
improves adjusting for the age of patient (b=− .050, p = .036, R2 = 0.057).
To determine if this unexpected variability was associated with chromosome 4 or chromosome
10 alleles, we specifically measured the D4Z4 methylation status at 4q35 using the MSRE2 testing
in 110 subjects with a suitable 4/2 chromosomal profile (see Methods and Figure S1). Using this
4q35-specific DNA methylation test, we still detected a highly variable D4Z4 methylation level ranging
from 0% to 85% (Figure 1B). Statistical analysis revealed a very weak relationship between the level
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of D4Z4 methylation at 4q35 and the FSHD score (b = −0.050, p = 0.036, R2 = 0.057). We conclude
that DNA methylation at chromosome 4q35 is highly variable in FSHD1 subjects and is not a strong
indicator of disease severity.
2.2. Analysis of D4Z4 Methylation in FSHD1 and FSHD2
It has been reported that D4Z4 methylation level is lower in FSHD2 than in FSHD1 because all four
D4Z4 arrays (2 at 4q35 and 2 at 10q26) are epigenetically dysregulated [20,21]. Originally, the threshold
of 25% of total D4Z4 DNA methylation was used as a cutoff to identify FSHD2 affected subjects [22].
In a later work, the threshold was subsequently moved up to 30% [28]. In our cohort, we found that
out of 34 index cases with classical FSHD phenotype carrying normal-sized D4Z4 alleles at 4q (FSHD2),
18 (52.9%) displayed CpG methylation levels higher than the 25% cutoff, assessed with the MRSE2
assay. To test whether D4Z4 methylation at the proximal FseI site supports the identification of FSHD2,
we measured the difference in the mean level of D4Z4 methylation obtained using MSRE1 and MSRE2
between FSHD1 (n = 88) and FSHD2 group (n = 34) of index cases (Figure 2). As presented in Table 1,
our analysis did not reveal a significantly different D4Z4 methylation level (∆ MSRE1 = 4.7, p = 0.108;
∆ MSRE2 = −3.6, p = 0.275).
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Figure 2. Comparison of D4Z4 DNA methylation level between FSHD index cases carrying 1–10 D4Z4
repeat units (RU) (FSHD1) or more than 10 D4Z4 RU (FSHD2): A box plot of D4Z4 methylation level
assessed with MSRE1 (A) and MSRE2 (B) approaches in carriers of 1–10 or >10 D4Z4 units. The circle
indicates an outlier value.
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Table 1. Mean D4Z4 methylation level and difference (∆) in mean D4Z4 methylation between two
groups reported in Figure 2.
FSHD
Index
Cases
D4Z4 (RU)
Number
of
Subjects
Mean D4Z4
Methylation
Level (%)
SD SE
Difference in Mean D4Z4
p-ValueMethylation between Two
Groups
∆
MSRE1
1–10 88 36.3 11.9 1.3
4.7 0.108
>10 34 31.6 19.5 3.3
MSRE2 1–10 82 28.0 12.0 1.3 −3.6 0.275
>10 28 31.6 21.5 4.1
SE = Standard error; SDS = Standard deviation.
2.3. Analysis of D4Z4 DNA Methylation in FSHD Families
To verify whether D4Z4 methylation status can be a reliable prognostic marker in FSHD,
we analyzed relatives carrying the same molecular defect at 4q35 and presenting classical FSHD
(categories A1, A2, A3), or incomplete (categories B1 and B2) or complex (categories D1 and D2)
phenotype or relatives with no muscle impairment (categories C1 and C2). Figure 3, Table 2, and Table
Sb show the distribution of methylation percentages of 232 individuals stratified over clinical categories
in two groups of subjects, probands and relatives. A similar result was obtained by using the MSRE2
assay (Figure 3B). As shown in Figure 3A and Table 2, the mean D4Z4 methylation levels detected with
MSRE1 assay in subjects belonging to the different clinical categories (A, B, and D) ranges between 33%
and 38.3%, including healthy subjects (category C).
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Figure 3. Evaluation of D4Z4 methylation levels in subjects belonging to different clinical categories: A
box plot of D4Z4 methylation levels assessed with MSRE1 assay (A) and MSRE2 (B) in probands and
relatives stratified over clinical categories (A, B, C, and D).
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Table 2. The mean D4Z4 methylation values for the MRSE1 assay graphed in Figure 3A and the 95%
confidence interval (CI).
MSRE1 Clinical Category Mean D4Z4 Methylation Level 95% CI
index cases A1 34.3 [28, 40.6]
A2 33.2 [33.2, 37.6]
A3 37 [33.4, 40.8]
relatives A1 33 [16.2, 49.8]
A2 33.2 [23.5, 42.9]
A3 31.1 [26.4, 35.9]
B1 37.3 [26.1, 48.5]
B2 34.1 [29.5, 38.7]
C1 37.1 [27.7, 46.5]
C2 38.3 [35.2, 41.4]
D1 41 [35.2, 46.8]
D2 39 [29.2, 48.8]
2.4. Evaluation of the Predictive Value of D4Z4 DNA Methylation in FSHD
To verify the value of D4Z4 DNA methylation in predicting the FSHD status, we compared D4Z4
methylation level in relatives with classical FSHD phenotype (category A) and unaffected relatives
(category C). The performance of a model based on methylation at D4Z4 repeats as a discriminator
between pathogenic and healthy condition was analyzed using the receiver operating characteristic
(ROC) curve. The ROC curve in Figure 4 shows that D4Z4 methylation status is a poor predictor
of disease status, as the calculated area under the curve (AUC) is not significantly different from
0.5 as reported in Table 3. MSRE1 analysis suggested that the D4Z4 methylation status might instead
aggregate in a family pattern (data not shown) rather than being a general mark of FSHD.
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Table 3. The area under the curve (AUC) threshold of the model.
Test Result Variables AUC SE Asymptotic 95% CI
MSRE1 0.622 0.1 [0.5,0.8]
MSRE2 0.592 0.1 [0.5,0.7]
AUC = Area under curve; SE = Standard Error; CI = 95% Confidence Interval.
2.5. Analysis of D4Z4 Methylation Status and Reduced Penetrance in FSHD Families
We further investigated the prognostic and diagnostic values of D4Z4 methylation in FSHD1
families with reduced penetrance (Table Sc for details). In one family, Family C, the 4q-contracted
allele (4RU) was detected in eleven people. As shown in Figure 5A, subjects (II·2, III·6, III·9, IV·3,
and IV·5) aged 91, 59, 57, 53, 36, and 39, respectively, did not show any sign or symptom of disease
(FSHD score 0). Six (III·1, III·3, III·5, III·7, IV·1, and IV·2) presented the clinical features characteristic
of FSHD (category A, FSHD score ≥1). We first performed 4q haplotyping followed by a BSS assay,
which specifically analyzes the most telomeric 4qA- or 4qA-L-associated D4Z4 RU (BSSA or BSSL,
respectively) in all family members carrying DRA (Figure 5 and Table Sc). The haplotyping revealed
the presence of one 4qA161 allele and one 4qB163 allele in all subjects except II-1 (4qB163/4qB163),
II-2 (4qA161/4qA161), and IV-3 (4qA161/4qA-L161), with the 4qA161 being 4 RUs and the other 4q
chromosome of normal size (17 RU or 22 RU D4Z4 in all subjects except in III·1 (4qA161 30 RU)).
To avoid diluting the values by averaging with the methylation levels of the non-contracted array in
4qA161/4qA161 subjects, we used the first quartile (Q1) for the BSS methylation status. The obtained
BSS percent methylation for the Q1 of all analyzed alleles are provided in Table Sc. As shown in
Figure 5, we found that among the six clinically affected subjects the Q1 D4Z4 methylation ranged
between 6.3% and 28.6% and among the healthy relatives with DRAs the Q1 D4Z4 methylation ranged
between 3.6% and 17.0%. Low methylation levels were detected in four affected (III·1, III·3, III·5,
and IV·2) but also in four unaffected family members (III·6, III·9. IV·3, IV·5). The highest level of D4Z4
methylation in the family was observed in the affected IV·1 subject (Q1 methylation = 28.6), and the
lowest (Q1 methylation = 3.6) in the unaffected III·9 subject. Thus, while this BSSA assay accurately
identified all subjects in the family with a DRA as having low DNA methylation levels [27], the Q1
percent methylation did not correlate with disease presentation or severity, similar with what has been
previously reported for families with reduced disease penetrance [29].
In a second family, Family A, two (I·1 and II·1) out of five carriers of 4qA contracted alleles
(6 RU D4Z4) presented the clinical features characteristic for FSHD, with FSHD scores 7/15 and
6/15, respectively (Figure 6). Three additional carriers (II·2, II·3, and II·5) did not show any sign or
symptom of disease (FSHD score = 0/15). The BSS approach again enabled us to distinguish the
4qA161 contracted allele, which has been transmitted from the affected father I·1 to his children, II·1,
II·2, II·3, and II·5, from the non-contracted 4qA-L161 allele with 32 D4Z4 RU (Figure 6). Using BSS,
we observed that DNA methylation of the contracted 4qA-D4Z4 alleles ranged from 8.0% to 31.3%.
Again, the lowest level of methylation (8.0%) was detected in a clinically unaffected relative, II·3. Our
analysis also showed that the D4Z4 methylation of the 32 RU D4Z4 allele is above 73% regardless of
clinical diagnosis (Figure 6).
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Figure 5. Analysis of the D4Z4 methylation status in Family C. (A) Pedigree of family C. The genetic
profile (A) or the clinical and epigenetic features (B) of each individual are reported. Filled symbols
represent affected people. (C) Genomic DNAs from the selected individuals were analyzed using the
4qA or 4qA-L sodium bisulfite sequencing (BSS) assay. The percent DNA methylation for the Q1 is
indicated. Red boxes indicate methylated CpGs, blue boxes indicate unmethylated CpGs, and white
boxes indicate no CpG at the expected site.
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represent affected people (C) Genomic DNAs from the selected individuals were analyzed using the
4qA or 4qA-L BSS assay. The percentage methylation for the Q1 is indicated. Red boxes indicate
methylated CpGs, blue boxes indicate unmethylated CpGs, and white boxes indicate no CpG at the
expected site.
2.6. D4Z4 DNA Methylation Analysis in A Fully Penetrant FSHD1 Family
To further investigate the possibil ty that the D4Z4 methylation status might depend on the family
background, we identified a family with severe facial, shoulder girdle, and pectoral muscle weakness
and generalized atrophy (family B). The affected father had four affected children, two daughters and
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two sons (II·1, II·2, II·3, II·4) (Figure 7). All were wheelchair-bound from 30, 30, 38, and 18 years of age,
respectively. All subjects reported age at onset in the second decade of life. Routine molecular testing
and BSS analysis revealed the presence of two permissive D4Z4 alleles, one 4qA161 in the healthy
range (32 RU D4Z4) and one 4qA-L161 D4Z4 with 2 RU. As shown in Figure 7, the DNA methylation
of the distal 4qA D4Z4 region assessed by BSS methodology revealed high CpG DNA methylation
content (≥50%) in all family members on the non-contracted (32 U) allele. However, the contracted
(2 RU) 4qA-L showed a wide range of methylation levels (10%–30%) despite similar FSHD scores and
the levels, again, the methylation status did not correlate with disease severity. Thus, in Family B,
we failed to detect reduced D4Z4 methylation using this BSS technique in the affected family members.
We concluded that in this family the D4Z4 methylation status is not associated with a very severe
clinical status.
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3. Discussion
D4Z4 hypomethylation has been associated with disease in individuals with a short D4Z4
array [20,24,26,28,29]. In recent years, D4Z4 hypomethylation has been proposed as a reliable marker
and additional diagnostic tool for ide tifying DRA associated with FSHD nd to distinguish classic l
FSHD from FSHD2 [22,24,27–29]. Several diagnostic schemes using BSS for assessing D4Z4 ethylation
status have been proposed [24,27]. To test the general v lue of methylation in a diagnostic algorithm
for FSHD, we selected 122 unrelated FSHD index cases presenting facial and scapular girdle muscle
weakness typic l of FSHD, classified as clinical category A based on the Compreh nsive Clinical
Ev luation Form (CCEF) [19]. Using MSRE analysis, we observed a wide variability i the level of
methyl tion among index cases with no association with clinical manifestation or severity f t e
disease. Thi ariability was de ected also when we restricted our an lysis exclusively to the 4q35
alleles. Higher FSHD scores do not appe r t be associated with very low levels of methylation,
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even in families with extreme clinical manifestation of disease, such as family B (Figure 7). Overall,
our MSRE analysis failed to detect a particular D4Z4 methylation pattern in FSHD index cases.
This indicates that D4Z4 methylation is not broadly predictive of disease severity, consistent with
previously published studies that reported DNA hypomethylation on 4q35 DRA in FSHD family
members that showed no clinical manifestation of the disease [28–30]. However, D4Z4 methylation
status has been proposed as a valuable tool in families with reduced penetrance for identifying DRAs
in apparently healthy individuals since the DRA typically has an intermediate level of D4Z4 DNA
methylation in asymptomatic relatives that is significantly lower than that found in healthy relatives
lacking a DRA [29]. Our BSS data of Families A, B, and C is consistent with this model.
It is also known that all FSHD affected family members do not necessarily display the typical
FSHD phenotype (category A) and may belong to different clinical subcategories (from B to D) [13,18].
In addition, the presence of a high number of unaffected relatives carrying DRAs increases the difficulty
in predicting a possible clinical outcome and complicates FSHD genetic counseling [16]. Therefore,
we extended our methylation analysis to all available family members carrying a D4Z4 reduced allele.
We analyzed 110 relatives belonging to different clinical subcategories (A to D) to test whether D4Z4
methylation might be associated with clear manifestations of disease. In this group, we had subjects
with classical FSHD (categories A1, A2, A3), as well as subjects within complete (categories B1 and B2)
or complex (categories D1 and D2) phenotypes or relatives with no muscle impairment (categories C1
and C2). Remarkably, the mean D4Z4 methylation levels detected in subjects belonging to the different
clinical categories (A, B, and D) and healthy subjects (category C) did not permit to discriminate
between the different clinical categories. Indeed, by extending the methylation analysis to affected
(category A) and non-affected (category C) family members we established that the D4Z4 methylation
test has a low positive predictive value for the identification of clinical FSHD.
MSRE D4Z4 methylation test was also proposed to be efficacious in distinguishing cases carrying
D4Z4 reduced allele at 4q35 (FSHD1) and those carrying 4q35 alleles of normal size (FSHD2). Data from the
literature suggest that total D4Z4 hypomethylation is more pronounced (≤25% across all 4 D4Z4 arrays)
in FSHD2 individuals with mutations in SMCHD1 or DNMT3B [22,31] compared to FSHD1 and that this
epigenetic modification characterizes the FSHD2 group of patients [12,21,25]. Here, using MSRE analysis,
we failed to observe a significantly different mean level of total D4Z4 DNA methylation between FSHD1
and FSHD2 subjects. Importantly, we found a group of individuals with classical FSHD phenotype carrying
normal-sized 4q35 D4Z4 alleles that display CpG methylation >25%.
Therefore, given the apparent lack of predictive ability of the FseI methylation data, it appears
that D4Z4 methylation testing in FSHD diagnostic practice should not be recommended as predictive
of disease, but it might be used for a better characterization of individual families.
Besides, both BSS analysis and MRSE data were concordant and both showed a lack of association
between D4Z4 methylation level and the clinical status. As an example, in family B with very severe
classical phenotype we found a D4Z4 methylation of 30%, ruling out any putative correlation between
disease severity and hypomethylation. In agreement with this, we found a low level of methylation in
healthy subjects that contained a DRA (i.e., subject II.3 in family A, Figure 5).
In contrast with early epigenetic studies on FSHD [32–34], our findings indicate that D4Z4
hypomethylation is not strictly associated with the presence of the FSHD typical clinical presentation
and suggest that results of D4Z4 methylation analysis must be cautiously interpreted in respect to
disease prognosis, in agreement with recent epigenetic studies [28,29]. Indeed, our study shows that
subject selection based on strict clinical criteria is fundamental to define a diagnostic strategy in FSHD.
In fact, in agreement with our findings, the first step of a proposed DNA methylation diagnosis of
FSHD is to start with a clinical diagnosis consistent with FSHD or to be a first-degree relative of
an individual diagnosed with FSHD [27]. It is possible that the inclusion of subjects without a precise
clinical description might introduce bias, reducing the possibility of identifying true biomarkers.
The study also has some limitations. It would be advisable to verify these data in additional studies
on cohorts of subjects in whom the standardized clinical assessment would be applied, extending the
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BSS analysis to a larger number of selected subjects. A general issue in epigenetic analyses is
that cell models might not share the epigenetic signature of primary cells targeted by the disease.
Obtaining a consistent number of muscle biopsies from index cases and relatives represent a challenge
which would provide more exhaustive response to questions that are posed for clinical purposes.
4. Materials and Methods
4.1. Participants
Our study was performed on FSHD families recruited through the Italian Clinical Network for
FSHD (ICNF) (www.fshd.it). All clinical and molecular data were collected in the Miogen database and
the Italian National Registry for FSHD (INRF) (www.fshd.it). Signed informed consent was obtained
from each subject before inclusion in the study.
Clinical status was ascertained using the Comprehensive Clinical Evaluation Form (CCEF),
which evaluates the distribution and degree of motor impairment [19]. The CCEF has been developed
by the ICNF to classify subjects based on their clinical features. The CCEF classifies: 1) subjects
presenting facial and scapular girdle muscle weakness typical of FSHD (category A, subcategories
A1-A3), 2) subjects with muscle weakness limited to scapular girdle or facial muscles (category B
subcategories B1, B2), 3) asymptomatic/healthy subjects (category C, subcategories C1, C2), 4) subjects
with myopathic phenotype presenting clinical features not consistent with FSHD canonical phenotype
(D, subcategories D1, D2). The degree of clinical severity was assessed by using the FSHD clinical
scale, which evaluates distinct muscle groups independently and translates disability into a number,
the FSHD score. The FSHD score ranges from zero, when no objective evidence of muscle functional
impairment is present, to 15, when all the muscle groups tested are severely impaired [35].
We enrolled 122 index cases presenting facial and scapular girdle muscle weakness typical of
FSHD (category A, subcategories A1–A3) (Figure S1a). Clinical and molecular assessments were
extended to 110 family members belonging to 60 unrelated families (Figure 8 and Table Sb). In the
remaining 62 index cases, the family study was not possible because they were either de novo DRA
carriers (17 subjects) or isolated cases (45 subjects) for whom no additional relatives were available.
Out of 122 index cases (mean age at examination of 48·5 years), 73 (59.8 %) were male.
Among 110 relatives (mean age at examination of 45.3 years), 49 (44.5%) were male (Table 4).
Table 4. Baseline characteristics of selected participants.
Number of
Subjects
Sex Age atExamination D4Z4 (RU)
male female mean SD 1–10 >10
index
cases 122 73 (59.8%) 49 (40.1%) 48.5 18.5 88 34
relatives 110 49 (44.5%) 61 (55.4%) 45.3 15.5 107 2
All individuals were molecularly characterized by the routine diagnostic molecular test for the
assessment of the size of D4Z4 arrays at 4q35. Through this approach, we established whether the
individual presented standard allele constitution of two 4-type D4Z4 arrays on chromosome 4 and two
10-type D4Z4 arrays on chromosome 10, here termed chromosomal profile 4/2, or alleles deriving from
different 4q-10q translocations and resulting in chromosomal profiles with apparently altered ratios
termed 4/1 and 4/3, as shown in Figure S1A.
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4.2. Clinical Investigation
In this study, all subjects recruited were examined by applying the Comprehensive Clinical
Evaluation Form (CCEF), a recently published standardized clinical tool with inter-rater reliability [19].
The CCEF consists of four sections. The first section (Evaluation Form) investigates the subject’s
clinical history and the patient’s disability and assesses muscle segmental involvement. The second
section includes the FSHD Evaluation Scale to calculate the FSHD clinical score (range from 0 to
15) [35]. The combination of the clinical features suggestive or not of FSHD, summarized in the
Clinical Diagnostic Form, assigns patients to different Phenotypic Categories. In particular, (1) subjects
presenting facial and scapular girdle muscle weakness typical of FSHD are classified as category A,
subcategories A1–A3; (2) subjects with muscle weakness limited to scapular girdle or facial muscles
are category B, subcategories B1, B2, respectively; (3) asymptomatic/healthy subjects are category C,
subcategories C1, C2; (4) subjects with myopathic phenotype presenting clinical features not consistent
with FSHD canonical phenotype are category D, subcategories D1, D2.
4.3. Molecular Analysis for 4q35 and 10q26
DNA was prepared from isolated lymphocytes according to standard procedures. In brief,
restriction endonuclease digestion of DNA was performed in agarose plugs with the appropriate
restriction enzyme: EcoRI, EcoRI/BlnI. Digested DNA was separated by PFGE in 1% agarose gels as
previously described [10].
Allele sizes were estimated by Southern hybridization with the p13E-11 probe of 7µg of
EcoRI-EcoRI/BlnI-digested genomic DNA extracted from peripheral blood lymphocytes, electrophoresed
in 0.4% agarose gel, for 45–48 h at 35 V, alongside an 8–48 kb marker (Bio-Rad, Bio-Rad Laboratories S.r.l.,
CA, USA) (Figure S1A). To distinguish whether the D4Z4-reduced allele originates from chromosome
10q or 4q, DNA from each index case was analyzed by NotI digestion and hybridized with the B31
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probe [10]. Restriction fragments were detected by autoradiography or using a Typhoon Trio system
(GE Healthcare Chicago, IL, US).
4.4. Methylation-Sensitive Restriction Enzyme (MSRE) Analysis
DNA was prepared from isolated lymphocytes according to standard procedures.
By Methylation-Sensitive Restriction Enzyme (MSRE) approach, we investigated the status of DNA
methylation at CpGs positioned at the most proximal D4Z4 repeat in (1) both chromosomes 4q and
chromosome 10q (MSRE1) or (2) exclusively in chromosomes 4q excluding chromosomes 10q (MSRE2)
(Figure S1A).
In brief for MSRE1, 5 µg of genomic DNA were digested with restriction enzyme BglII (NEB)
and subsequently with the FseI methylation-sensitive restriction enzyme (NEB). DNA digested with
BglII/FseI was separated in 0.8% agarose gel for 24 h. MSRE1 test allowed obtaining the level of D4Z4
DNA methylation in all 122 FSHD index cases and their 110 relatives. For MSRE2, 5 µg of genomic
DNA was digested with restriction enzymes BglII (NEB) and with BlnII (NEB) followed by FseI (NEB)
digestion. DNA digested with BglII/BlnI/FseI was separated in 0.8% agarose gel for 24 h. MSRE2 was
performed in the subjects presenting 4/2 chromosomal profile; 110 FSHD index cases and 102 relatives
were suitable for this analysis (Table 4). Southern blotting and radioactive hybridization of MSRE1-
and MSRE2-digested DNA were performed using the probe p13E-11. MSRE1- or MSRE2-digested
DNA fragments were detected by autoradiography with the Typhoon Trio system (GE Healthcare),
and the signal intensities were acquired and quantified with the Image Quant software. The final result
is presented in percentage of methylation calculated as the ratio between digested (hypomethylated)
and undigested (methylated) DNA.
4.5. Sodium Bisulfite Sequencing (BSS)-DNA Methylation Analysis
Genomic DNA samples extracted from lymphocytes were bisulfite converted, amplified using
primers specific for the distal 4qA and 4qA-Long (4qA-L) D4Z4 repeat regions, and then sequenced,
as described [27]. This BSS assay is specific for analyzing the DNA methylation status of the most
distal D4Z4 unit on permissive 4qA chromosomes by utilizing polymorphisms in the primers that
are exclusive to 4qA and not found in 10qA or 4qB. The 4qA BSS assay analyzes 56 CpGs in the most
telomeric D4Z4 RU on 4qA-containing chromosomes. A fraction of chromosomes characterized as 4qA
are an allelic variant termed 4qA-L; these contain an additional 2 kb of D4Z4 sequence at the distal
repeat although the A-type subtelomere is unchanged. Thus, the 4qA-L BSS assay utilizes the same
4qA-specific reverse BS-PCR primers as the 4qA assay but analyzes a distinct set of 30 CpGs in the
distal repeat on 4qA-L chromosomes, as described in Reference [27]. To account for differences in the
number of assayable 4q alleles in subjects (1 or 2), DNA methylation from this BSS assay is reported in
methylation percentage quartiles for each linearly sequenced chromosome, calculated such that with n
chromosomes ordered highest methylation to lowest methylation, the first quartile (Q1) is methylation
of the n/4-th chromosome. If n/4 is not an integer, then interpolation is used between the nearest values.
Thus, the greater the n chromosomes assayed, the higher the confidence in the presented Q1 values.
Q1 value less than 25% for 4qA assay and Q1 value less than 30% for 4qA-L assay are characterized
as FSHD.
4.6. Statistical Analysis
Characteristics of subjects were compiled using established descriptive statistics. To quantify the
possible relationship between continuous variables (D4Z4 methylation level, FSHD score), we carried
out linear regression analysis. To compare means (D4Z4 methylation percentage, FSHD score), we used
t-test and analysis of variance (ANOVA, graphPad Prism version 8.00 for Windows, GraphPad Software,
San Diego, CA, USA). To establish the relationship between disease status and methylation percentage,
we constructed receiver operating characteristic (ROC graphPad Prism version 8.00 for Windows,
GraphPad Software, San Diego, CA, USA) curves.
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4.7. Ethical Statement
The study was approved by the Local Ethics Committees of all participating Institutions. The study
was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki
and its later amendments.
5. Conclusions
In conclusion, the variability in D4Z4 methylation observed in our purposefully selected cohort of
clinically homogeneous patients and their healthy relatives, as well as the detection of pronounced
D4Z4 hypomethylation below the 25% threshold in only half of phenotypic FSHD2 cases, show that
this epigenetic mark has a low predictive clinical value. Therefore, D4Z4 methylation can accurately
identify DRAs in FSHD families. DNA methylation analysis alone is insufficient as a prognostic and
diagnostic tool for disease presentation and severity and should be properly complemented with
a standardized clinical assessment and proper family studies.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/7/2635/
s1.
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